Simulations Plus, Inc. (NASDAQ:SLP) Receives $50.00 Average PT from Analysts

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) has been assigned an average recommendation of "Buy" from the seven ratings firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $50.00.

Several research firms have recently weighed in on SLP. KeyCorp lifted their price target on shares of Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday, April 16th. StockNews.com raised shares of Simulations Plus from a "sell" rating to a "hold" rating in a research note on Monday, April 28th.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $33.51, for a total transaction of $670,200.00. Following the completion of the transaction, the director now directly owns 3,344,157 shares in the company, valued at $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 19.40% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLP. Proficio Capital Partners LLC acquired a new position in shares of Simulations Plus during the 4th quarter worth approximately $719,000. Barclays PLC grew its stake in shares of Simulations Plus by 390.6% in the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company's stock valued at $911,000 after buying an additional 22,669 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Simulations Plus by 106.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company's stock worth $1,517,000 after purchasing an additional 24,371 shares during the period. Sei Investments Co. purchased a new position in shares of Simulations Plus during the 4th quarter worth approximately $330,000. Finally, Tributary Capital Management LLC boosted its position in Simulations Plus by 21.7% in the 4th quarter. Tributary Capital Management LLC now owns 396,093 shares of the technology company's stock valued at $11,047,000 after buying an additional 70,526 shares during the period. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Stock Performance

NASDAQ SLP traded up $0.28 during trading on Monday, hitting $31.10. The stock had a trading volume of 229,173 shares, compared to its average volume of 209,391. The stock has a market capitalization of $625.45 million, a price-to-earnings ratio of 77.75 and a beta of 1.10. Simulations Plus has a one year low of $23.01 and a one year high of $51.22. The stock has a 50 day simple moving average of $28.80 and a 200 day simple moving average of $30.23.

Simulations Plus (NASDAQ:SLP - Get Free Report) last announced its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. During the same quarter last year, the firm earned $0.20 earnings per share. The firm's quarterly revenue was up 22.5% compared to the same quarter last year. On average, sell-side analysts predict that Simulations Plus will post 1.09 EPS for the current year.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.